Cymbalta Fact Sheet
Eli Lilly; patent expires 2008.
Major Depressive Disorder
- Diabetic Peripheral Neuropathic Pain
- Off-label use for fibromyalgia and GAD
Serotonin Norepinephrine Reuptake Inhibitor (SNRI)
Supplied in 20 mg, 30 mg, and 60 mg delayed-release capsules.
- For most patients, start at 30 mg QHS, with target dose of 30 mg BID.
- Can also be dosed 60 mg QHS for patient convenience.
Most common are nausea; dry mouth; constipation; decreased appetite; fatigue; somnolence; and increased sweating. Probably less of a risk of hypertension than Effexor XR. Anecdotal reports of significant discontinuation reactions (on a par with Effexor XR).
- Postmarketing surveillance has revealed cases of hepatitis in patients with histories of “substantial alcohol use” or with chronic liver disease, so it is risky to prescribe Cymbalta to either of these populations.
Metabolized by CYP 1A2 and CYP 2D6; inhibitors of these enzymes, including Prozac, Paxil, Luvox, and some antibiotics and antiarrhythmic drugs, can increase exposure to Cymbalta.
- Cymbalta may potentiate the effects of alcohol and CNS acting drugs; it is contraindicated for use with MAOIs.
- Pregnancy Risk Category C
Cymbalta is becoming the first-line treatment for depressed patients who also have some type of somatic pain, even if this is something other than the approved use for diabetic peripheral neuropathy.
Current Issue
Topics
Search
Follow Us
Earn CME Credit Instantly!
Not quite ready for a one-year subscription to The Carlat Psychiatry Report? Need CME credits on a particular topic or on a tight deadline?
Try our A la Carte CME! You can buy single or multiple credits of continuing education, without committing to a year-long newsletter subscription.
Click here to purchase A la Carte CME credits
Already an A la Carte subscriber? Click here to go to your a la carte page
Steve Balt Interviewed by NPR
Our own Steve Balt was interviewed on NPR's "Talk of the Nation" on psychiatry's shift toward drugs and away from talk therapy.
Editor-in-Chief
After 10 years at the helm of TCPR, Dr. Carlat has handed over editor-in-chief duties to Dr. Steve Balt. We’re excited to welcome him aboard! Read More...
The 2012 Carlat Atypical Antipsychotics Table is Now Available!
With all the atypicals on the market, it's hard to keep track of indications, dosages, and all the other relevant facts for each drug. Use this table for summaries on these meds, their uses, their side effects, and a whole slew of other information.
TCPR Continuing Education
Accredited/Approved/Accepted by:
- ACCME
- AMA
- APA
- ABPN
- ANCC
- AAPA